How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,092 results for

Depo Provera

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

241. Extended Duration Varenicline for Smoking Among Cancer Patients: A Clinical Trial

and spermicide, oral contraceptive, Depo-Provera injection, contraceptive patch, tubal ligation) or abstain from sexual intercourse during the time they are taking study medication and for at least one month after the medication period ends. Able to communicate fluently in English. Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the combined consent/HIPAA form. Exclusion Criteria: Subjects who present with and/or self-report the following

2016 Clinical Trials

242. A Study of LGD-6972 in Patients With Type 2 Diabetes Mellitus

female partners will use 2 acceptable forms of contraception, one of which must be a condom, until 30 days after the last dose of study drug. Other acceptable forms of contraception include hormonal contraceptives that have been at stable dose for 12 weeks prior to randomization, intrauterine device, Depo-Provera®, Norplant® System Implants, bilateral tubal ligation, bilateral oophorectomy, hysterectomy, and contraceptive sponge, foam, or jelly. Also, male subjects must not donate sperm during

2016 Clinical Trials

243. Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML)

effective contraceptive methods during the study. Adequate forms of contraception are double barrier methods (condoms with spermicidal jelly or foam and diaphragm with spermicidal jelly or foam), oral, depo provera, or injectable contraceptives, intrauterine devices, and tubal ligation. Male patients with female partners who are of childbearing potential: Recommendation is for male and partner to use at least 2 effective contraceptive methods, as described above, during the study. Females must

2016 Clinical Trials

244. Pancreatic Islet Transplantation Into the Anterior Chamber of the Eye

de-novo). For female subjects: Positive pregnancy test, presently breast-feeding, or unwillingness to use effective contraceptive measures for the duration of the study and 4 months after discontinuation. For male subjects: intent to procreate during the duration of the study or within 4 months after discontinuation or unwillingness to use effective measures of contraception. Oral contraceptives, Norplant®, Depo-Provera®, and barrier devices with spermicide are acceptable contraceptive methods

2016 Clinical Trials

245. Study of CD133KDEL Toxin in the Treatment for Solid Tumors

or prior known impairment is present. Females of childbearing potential and males who have partners of childbearing potential must agree to use 2 effective contraception methods, one of which must be a barrier method, during the study and for ≥12 weeks after the last dose of dCD133KDEL. Effective methods include intrauterine device (IUD), Depo-Provera injection or implant, Evra patch, NuvaRing, oral contraception, and diaphragm/spermicide with condom. Ability to understand and provide voluntary written

2016 Clinical Trials

246. Effect of Food on the Bioavailability of 15 mg Estetrol/3 mg Drospirenone Tablets in Healthy Female Volunteers

hormonal method of contraception (e.g., Depo-Provera) during the last 6 months prior to the first dose. Use (within 28 days prior to first dose) of other hormonal contraceptive method. Use of any prescription drugs (except thyroid hormone supplements) or herbal supplements acting on CYP3A4 functions (e.g., St. John's Wort), within 28 days prior to the first dose until study completion, any over-the-counter (OTC) medication (including paracetamol) or dietary supplements (vitamins included) within 14

2016 Clinical Trials

247. Four Way Crossover Closed Loop With Exercise Detection

all clinic visits. Willingness to sign informed consent and HIPAA documents. Exclusion Criteria: Female of childbearing potential who is pregnant or intending to become pregnant or breast-feeding, or is not using adequate contraceptive methods. Acceptable contraception includes birth control pill / patch / vaginal ring, Depo-Provera, Norplant, an IUD, the double barrier method (the woman uses a diaphragm and spermicide and the man uses a condom), or abstinence. Any cardiovascular disease, defined

2016 Clinical Trials

248. Evaluation of the Efficacy and Safety of LevoCept

intercourse earlier in current cycle Subject who anticipates separation from her partner for more than 1 cycle within the next 12 months; A previously inserted IUD that has not been removed by the time LevoCept is placed; History of previous IUD complications, such as perforation, expulsion, infection (pelvic inflammatory disease) or pregnancy with IUD in place.; Injection of hormonal contraceptive (e.g., Depo-Provera) within the last 10 months; 5.1 Must have had 2 normal menstrual cycles since the last

2016 Clinical Trials

249. E4/DRSP Single and Multiple Dose PK and Early QT Study

Previous participation in the current study Use of: combined contraceptives (i.e., COC, Nuvaring®) within 28 days prior to the first dose administration until study completion progestogen-only contraceptive methods (e.g., minipill, implant, or hormonal intrauterine system) within 28 days prior to the first dose administration until study completion depot progestogen preparations or an injectable hormonal method of contraception (e.g., Depo-Provera®) within 6 months prior to the first dose until study

2016 Clinical Trials

250. Study to Evaluate the Safety of Griffithsin in a Carrageenan Gel in Healthy Women

, it must be have been used for at least 30 days prior to screening, with no planned change in method during the study. The following forms of contraception (per self-report) are permitted: same-sex relationship, male or female sterilization, oral contraceptives, contraceptive implant, contraceptive patch, IUS, IUD depo-medroxyprogesterone acetate (DMPA; Depo-Provera®). 8) Willing to abstain from sexual intercourse/activity including receptive vaginal, oral, digital, and anal intercourse, and the use

2016 Clinical Trials

251. IV Tranexamic Acid Prior to Hysterectomy

, menorrhagia, uterine fibroids, adenomyosis, pelvic pain, dysmenorrhea, pelvic organ prolapse or endometriosis. Age ≥ 18 years Pre-operative hemoglobin >8 g/dl Willing to have IV tranexamic acid or a placebo prior to hysterectomy Ability to understand and the willingness to sign a written informed consent. Can be previously treated with Depo-Lupron, Depo-Provera, Oral Contraceptive pills, Mirena IUD, endometrial ablation, myomectomy, oral progestins Hysterectomy in combination with the following procedures

2016 Clinical Trials

252. Study of Pembrolizumab With or Without CC-486 in Patients With Platinum-resistant Ovarian Cancer

treatment. Recommendation is for 2 effective contraceptive methods during the study. Adequate forms of contraception are double-barrier methods (condoms with spermicidal jelly or foam and diaphragm with spermicidal jelly or foam), oral depo provera, or injectable contraceptives, intrauterine devices, and tubal ligation. Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other trial procedures. Exclusion Criteria: Non-epithelial ovarian cancers, including

2016 Clinical Trials

253. Compare Daily Ulipristal Acetate and Combined Oral Contraceptive Effects on Breast Epithelial Cell Proliferation

menstrual cycles (3 bleeding episodes) prior to screening. If previous use of injectable Depo Provera, subject must have had two normal menstrual cycles (3 bleeding episodes) prior to screening. Not at risk for pregnancy: Using a copper intra uterine device (IUD), or Willing to protect all further acts of intercourse with condoms, or Not hetero-sexually active, or Having undergone previous tubal ligation, or Partner sterilized or vasectomized. Body Mass Index (BMI) < 30 kg/m2 and not having previously

2016 Clinical Trials

254. Exploratory Study of Efficacy and Safety of Ingenol Mebutate 0.05% Gel for Common Warts on the Hands.

medically acceptable methods of birth control: Oral Contraceptives, Contraceptive patches, Contraceptive Injection (Depo-Provera®), Contraceptive Implant (Implanon™), Essure®, Vaginal Contraceptive (Nuva-Ring®), IUD, hormonal IUD (Mirena®); double-barrier methods (e.g. condom and spermicide), sterile partner (e.g., vasectomy performed at least six months prior to the subject's initiation of treatment) and abstinence with a documented second acceptable method of birth control should subject become

2016 Clinical Trials

255. LARC Forward Contraceptive Counseling at MHCC

are FDA approved. During the study participants will undergo counseling to choose the method of birth control that is right for them. This will include watching an informational video and having a discussion with study staff. If participants choose pills, the patch the ring, or a diaphragm and do not have any contraindications to this method, they will receive a prescription for this method to be filled at the pharmacy of their choice. If participants choose Depo-Provera (the shot), they will receive

2016 Clinical Trials

256. Long-Acting Progestin Contraception and the Vaginal Microbiome

: Observational Actual Enrollment : 28 participants Observational Model: Cohort Time Perspective: Prospective Official Title: Impact of Long-Acting Progestin Contraception on the Vaginal Microbiome Study Start Date : March 2016 Actual Primary Completion Date : June 1, 2018 Actual Study Completion Date : June 1, 2018 Resource links provided by the National Library of Medicine related topics: Groups and Cohorts Go to Group/Cohort Depo Provera Ten women ages 18-40 who elect to start a using Depo Provera (...) . If the hypothesis of a vaginal microbial shift with Depo Provera (DMPA) use is confirmed (our PRIMARY analysis), these tools will enable visualization of the differences. The tables of relative abundance of either taxonomic groups or metabolic pathways will be used to identify differential bacterial biomarkers present among patient and sample classes. Two bioinformatics tools particularly useful for biomarker discovery are LEfSe and MaAsLin (Multivariate Association with Linear Models, http

2016 Clinical Trials

257. Polyphenol/Prebiotic Blend Effects on GI Health and Microbial Composition

20-60 years of age Female subjects of childbearing potential must agree to use a medically approved method of birth control and have a negative urine pregnancy test result. Acceptable methods of birth control include: Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System) Double-barrier methods Non-hormonal intrauterine devices

2016 Clinical Trials

258. Study of Equivalence of Generic Pimecrolimus Cream 1% and Elidel® 1% in Subjects With Mild to Moderate Atopic Dermatitis

a medically accepted method of contraception during the study. The following are considered acceptable methods of birth control for the purpose of this study: oral contraceptives, contraceptive patches, contraceptive implant, vaginal contraceptive, double barrier methods (e.g., condom and spermicide), contraceptive injection (Depo-Provera®), intrauterine device (IUD), hormonal IUD (Mirena®), Essure® permanent birth control, and abstinence with a documented second acceptable method of birth control

2016 Clinical Trials

259. Substrate Utilization, Exercise Performance, and Skeletal Muscle Response to Energy Deficit and Altitude Acclimatization

birth control, NuvaRing®, Depo Provera®, etc.) Have supervisor approval (permanent party military) Not taking any medications and/or willing to refrain from all medication use 4 wk prior to and throughout the entire study period, unless provided/approved by the US Army Research Institute of Environmental Medicine (USARIEM) Office of Medical Support and Oversight (OMSO) or medical oversight at Pikes Peak, Colorado organized through OMSO. Willing to refrain from alcohol, smoking any nicotine product

2016 Clinical Trials

260. Efficacy of a LRCâ„¢ (L. Reuteri NCIMB 30242) Capsule on Managing Cholesterol in Adults

year since last menstruation) OR Female subject of childbearing potential must agree to use a medically approved method of birth control and have a negative urine pregnancy test result. Acceptable methods of birth control include Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System); Intrauterine devices; Vasectomy of partner

2016 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>